%20BIANCO.png)
Pipeline
Our compounds target components of the solid tumor microenvironment to foster anti-cancer immune response enhancing the recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors.
Our approach aims at reprogramming the solid tumor microenvironment to unlock the full potential of cancer immunotherapy.
SLC4A4
LVB 003
SCL4A4
is a bicarbonate transporter that induces bicarbonate uptake by cancer cells and increases TME acidity.
DP1/2
sustain TAMs immunosuppressive phenotype and impair CD8 T cell functions by prostaglandin D2 (PGD2) signaling.
LVB-004
DP1/2
P2Y6
LVB-005
P2Y6
Cytidine deaminase (CDA) is an enzyme of the pyrimidine salvage pathway that is involved in extracellular release of UTP and UDP. CDA-positive cancer cells recruit P2Y6-positive macrophages and sustain their immunosuppressive activity via UDP and UTP release.
Linoleic acid (LA)
is a major positive regulator of cytotoxic T lymphocyte activity by improving metabolic fitness, preventing exhaustion and stimulating a memory-like phenotype with superior effector functions.
LVB-006
LA
Join Lever Bio in advancing promising research and driving innovative drug development in the immuno-oncology field
News & Updates
SEMA3A
LVB 001
Mutant SEMA3A
is a PlexinA4-selective superagonist for cancer treatment that normalizes tumor vasculature and induces tumor-restraining CAF polarization.
PlexinA4
is a semaphorin receptor that negatively controls cytotoxic T lymphocytes migration in cancer.